Equivalency of Protection From Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons_ A Systematic Review and Pooled Analysis - PMC.pdf

Back to Top

12. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy. Vitale J, Mumoli N, Clerici P, et al. JAMA Intern Med. 2021;28:212959. [PMC free article] [PubMed] [Google Scholar]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627252/

20/22

5/18/22, 10:28 PM

Equivalency of Protection From Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic …

13. SEROCoV-POP study group. risk of reinfection after seroconversion to SARS-CoV- 2: a population-based propensity-score matched cohort study. Leidi A, Koegler F, Dumont R, et al. Clin Infect Dis. 2021;27:495. [PMC free article] [PubMed] [Google Scholar] 14. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Hansen CH, Michlmayr D, Gubbels SM, et al. Lancet. 2021;27:1204–1212. [PMC free article] [PubMed] [Google Scholar] 15. Reinfection rates among patients who previously tested positive for COVID- 19: a retrospective cohort study. Sheehan MM, Reddy AJ, Rothberg MB. Clin Infect Dis. 2021;15:234. [PMC free article] [PubMed] [Google Scholar] 16. Serologic status and SARS-CoV-2 infection over 6 months of follow up in healthcare workers in Chicago: a cohort study. Wilkins JT, Hirschhorn LR, Gray EL, et al. Infect Control Hosp Epidemiol. 2021:1–9. [PMC free article] [PubMed] [Google Scholar] 17. Vaccines and related biological products advisory committee meeting, December 10, 2020; FDA briefing document; PfizerBioNTech COVID-19 vaccine. [ Sep; 2021 ];https://www.fda.gov/media/144245/download 2020 18. Vaccines and Related Biological Products Advisory Committee Meeting, December 17, 2020; FDA Briefing Document; Moderna COVID-19 Vaccine.

[ Sep; 2021 ];https://www.fda.gov/media/144434/download 2020 19. Vaccines and Related Biological Products Advisory Committee Meeting, February 26, 2021 FDA Briefing Document; Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. [ Sep; 2021 ];https://www.fda.gov/media/146217/download 2021 20. Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: a three-month nationwide experience from Israel [Pre-Print] Goldberg Y, Mandel M, Woodbridge Y, et al. medRxiv. 2021 [Google Scholar] 21. Necessity of COVID-19 vaccination in previously infected individuals [Pre-Print] Shrestha NK, Burke PC, Nowacki AS, et al. medRxiv. 2021 [Google Scholar] 22. An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status. Lumley SF, Rodger G, Constantinides B, et al. Clin Infect Dis. 2021;3:608. [PMC free article] [PubMed] [Google Scholar] 23. Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May-June 2021. Cavanaugh AM, Spicer KB, Thoroughman D, et al. MMWR. 2021;13:1081–1083. [PMC free article] [PubMed] [Google Scholar] 24. ChAdOx1 nCoV-19 effectiveness during an unprecedented surge in SARS COV-2 infections. Satwik R, Satwik A, Katoch S, Saluja S. Eur J Intern Med. 2021 [PMC free article] [PubMed] [Google Scholar] 25.

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections [pre-Print] Gazit S, Shlezinger R, Perez G, et al. medRxiv. 2021 [Google Scholar] 26. Total Coronavirus Cases in Kentucky. [ Sep; 2021 ];https://www.worldometers.info/coronavirus/usa/Kentucky 2020 27. Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India [Pre-Print] Dhar MS, Marwal R, Radhakrishnan VS, Ponnusamy K, Jolly B, Bhoyar RC, Fatihi S, et al. https://www.medrxiv.org/content/10.1101/2021.06.02.21258076v1. Medrxiv. 2021 [PMC free article] [PubMed] [Google Scholar] 28. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Sheikh A, McMenamin J, Taylor B, Robertson C. Lancet. 2021;397:2461–2462. [PMC free article] [PubMed] [Google Scholar] 29. Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. Keehner J, Horton LE, Binkin NJ, et al. N Engl J Med. 2021;385:1330–1332. [PMC free article] [PubMed] [Google Scholar] 30. Waning immunity of the BNT162b2 vaccine: a nationwide study from Israel [Pre-Print] Goldberg Y, Mandel M, Bar-On YM, et al. MedRxiv. 2021 [Google Scholar] 31. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. Barda N, Dagan N, Ben-Shlomo Y, et al. N Engl J Med. 2021;385:1078–1090.

[PMC free article] [PubMed] [Google Scholar] 32. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a

Back to Top

prospective observational study. Menni C, Klaser K, May A, et al. Lancet Infect Dis. 2021;21:939–949. [PMC free article] [PubMed] [Google Scholar] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627252/

21/22

5/18/22, 10:28 PM

Equivalency of Protection From Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic …

Back to Top

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627252/

22/22